PMID- 19929456
OWN - NLM
STAT- MEDLINE
DCOM- 20100519
LR  - 20180629
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 12
IP  - 2
DP  - 2010 Apr
TI  - Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible 
      targets for immunotherapy.
PG  - 190-200
LID - 10.3109/14653240903390803 [doi]
AB  - BACKGROUND AIMS: Hepatocellular carcinoma (HCC) recurs with high frequency. 
      Characterization of recurrent HCC cells will facilitate the design of future 
      therapeutic strategies for recurrent HCC. METHODS: Two cell lines, Hep-11 and 
      Hep-12, were established from the same HCC patient's primary and recurrent tumor 
      tissues, respectively, and then analyzed for stem cell-like properties, immune 
      evasion strategies and immunogenicity. RESULTS: Compared with Hep-11 cells, 
      Hep-12 cells expressed higher levels of liver progenitor cell makers and 
      displayed persistent tumorigenic potential in the serial transplantation assay. 
      Although Hep-12 cells down-regulated human leukocyte antigen (HLA) class I 
      expression, they could still be recognized and killed by autologous-activated 
      tumor-infiltrating lymphocytes (TIL) in vitro. Pre-treatment with cytokines such 
      as tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) 
      increased the expression of HLA class I molecules on Hep-12 cells, and rendered 
      them more susceptible to CD8(+) T-cell-mediated recognition and TIL-mediated 
      cytotoxicity in vitro. CONCLUSIONS: Our results indicate that Hep-12 cells 
      possess stem cell-like properties, are susceptible to autologous-activated 
      TIL-mediated recognition and cytotoxicity, and pre-treatment with TNF-alpha and 
      IFN-gamma enhances their immunogenicity. This is the first evidence to support 
      the hypothesis that immunotherapy can be used to target recurrent HCC cells with 
      stem cell-like properties. This strategy may be an effective therapeutic approach 
      to prevent HCC recurrence and control recurrent HCC growth.
FAU - Xu, Xiaolan
AU  - Xu X
AD  - National Key Laboratory of Protein Engineering and Plant Gene Engineering, 
      Institute of Life Science, Peking University, Beijing, China.
FAU - Xing, Baocai
AU  - Xing B
FAU - Hu, Meihao
AU  - Hu M
FAU - Xu, Zuoliang
AU  - Xu Z
FAU - Xie, Yong
AU  - Xie Y
FAU - Dai, Guanghai
AU  - Dai G
FAU - Gu, Jun
AU  - Gu J
FAU - Wang, Yu
AU  - Wang Y
FAU - Zhang, Zhiqian
AU  - Zhang Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Lysosomal-Associated Membrane Protein 1)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Carcinoma, Hepatocellular/immunology/*pathology/prevention & control/*therapy
MH  - Cell Death
MH  - Cell Line, Tumor
MH  - Enzyme Assays
MH  - Humans
MH  - Immune Evasion/immunology
MH  - *Immunotherapy
MH  - Killer Cells, Natural/immunology
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Liver Neoplasms/pathology/*prevention & control/*therapy
MH  - Lymphocyte Activation/immunology
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Lysosomal-Associated Membrane Protein 1/metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Stem Cells/immunology/*pathology
MH  - Recurrence
MH  - Xenograft Model Antitumor Assays
EDAT- 2009/11/26 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - S1465-3249(10)70381-9 [pii]
AID - 10.3109/14653240903390803 [doi]
PST - ppublish
SO  - Cytotherapy. 2010 Apr;12(2):190-200. doi: 10.3109/14653240903390803.